Sutro Biopharma, Inc. · NASDAQ:STRO

Sutro Biopharma — J.P. Morgan Healthcare Conference 2023

21 slides from Sutro Biopharma's conference presentation, Jan 12, 2023

  1. Slide 1: J.P. Morgan Healthcare Conference

    J.P. Morgan Healthcare Conference January 12, 2023 Sutro Biopharma NASDAQ: STRO

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state

  3. Slide 3: Six Product Candidates in Clinical Development are Enabled by Sutro's Platform

    Six Product Candidates in Clinical Development are Enabled by Sutro’s Platform Unique engineering prowess in the field of precisely conjugated biologics, including next-gen ADCs Modality Program Target(s) Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Ovarian Cancer Fast Track Designa

  4. Slide 4: Achievements and Milestones

    Achievements and Milestones Clinical data readouts and partnerships provide multiple anticipated 2023 value drivers for Sutro Luvelta (STRO-002, FolRα ADC) STRO-001, CD74 ADC ✓ • Data on Phase 1 dose-expansion and regulatory path forward for the development of luvelta • Initiation by BioNova of clin

  5. Slide 5: Luveltamab Tazevibulin (Luvelta, STRO-002)

    Luveltamab Tazevibulin (Luvelta, STRO-002)

  6. Slide 6: Advanced Ovarian Cancer Has a High Unmet Medical Need

    Advanced Ovarian Cancer Has a High Unmet Medical Need Due to advanced stage of disease at diagnosis and limited progress of available treatments • Ovarian cancer is the most common cause of death from gynecological cancers – Accounts for 2.1% of all estimated cancer deaths(1,2) – Almost half of affe

  7. Slide 7: Two-Part Phase 1 Study for Patients with Advanced Ovarian Cancer

    LUVELTA Two-Part Phase 1 Study for Patients with Advanced Ovarian Cancer(1) Dose Expansion Explored dosing regimen and biomarker levels for which luvelta is optimal Part 1: Dose-escalation cohort Part 2: Dose-expansion cohort – Cohort A Part 2: Cohort C Ovarian Cancer 6.4 mg/kg Q3W Ovarian Cancer Fo

  8. Slide 8: Luvelta Phase 1 Data Establishes FolRα-Selection Criteria

    LUVELTA Luvelta Phase 1 Data Establishes FolRα-Selection Criteria Dose Expansion Cohort A Patients who started at the higher dose level demonstrated higher ORR and median PFS Dose-expansion efficacy data establishes TPS>25% as appropriate enrichment cutoff for luvelta Patients who started at 5.2 mg/

  9. Slide 9: Majority of FolRα-Selected Patients Experienced Disease Control

    LUVELTA Majority of FolRα-Selected Patients Experienced Disease Control Dose Expansion Cohort A FolRα-Selected 12 FolRα-selected patients demonstrated confirmed partial response BOR: Maximum Reduction in Tumor Target Lesions in FolRα-Selected Patients (N=32)(1) BOR in FolRα-Selected Patients (N=32)

  10. Slide 10: Patients Had Durable Responses even with Dose Modifications

    LUVELTA Patients Had Durable Responses even with Dose Modifications Dose Expansion Cohort A FolRα-Selected Patients who started at the higher dose experienced rapid time to response Starting Dose, 5.2 mg/kg (n=16)(1) 80 40 Dose Intensity by Starting Dose (N=44)(3) 65 80 90 5.2 mg/kg 4.3 mg/kg 100 Do

  11. Slide 11: Cohort C as a Deep Dive Into Managing Neutropenia

    LUVELTA Cohort C as a Deep Dive Into Managing Neutropenia Dose Expansion Cohort A & C Prophylactic use of pegfilgrastim reduced Grade 3+ neutropenia and dose delays Cohort A (patients at 5.2mg/kg starting dose) vs. Cohort C Part 2 Dose-expansion cohorts - Cohort A vs. Cohort C Grade 3+ Neutropenia a

  12. Slide 12: Most Common Treatment-Emergent Adverse Event was Neutropenia

    LUVELTA Most Common Treatment-Emergent Adverse Event was Neutropenia Dose Expansion Cohort A No new safety signals were observed, including the absence of meaningful drug-related ocular and lung AEs Most Common Grade 3+ TEAEs (≥2 Subjects) by Dose and General Category 4.3 mg/kg (n=23) 5.2 mg/kg (n=2

  13. Slide 13: Luvelta (STRO-002) Has a Favorable Product Target Profile

    LUVELTA Luvelta (STRO-002) Has a Favorable Product Target Profile Confidence to move forward into registrational-enabling study Potential to treat ~80% of patients with platinum- resistant ovarian cancer Efficacy demonstrated by ORR in the 31-44% range in FolRα-selected patients Manageable safety pr

  14. Slide 14: Luvelta Clinical Integrated Strategy for Phase 2/3 Study, REFRaME

    LUVELTA Luvelta Clinical Integrated Strategy for Phase 2/3 Study, REFRaME Integrated design to potentially support accelerated and full approvals in platinum-resistant ovarian cancer Part 1: Lead-In Dose Selection Part 2: Randomization Cohort A: 5.2 mg/kg IV Q3W with Selected Dose prophylactic Cohor

  15. Slide 15: Luvelta Provides Opportunities for Pipeline-in-a-Drug

    LUVELTA Luvelta Provides Opportunities for Pipeline-in-a-Drug Multiple shots on goal for commercial opportunities, beyond gynecological cancers Treatment Indication Estimated Market Size/Incidence Platinum-resistant Registrational-enabling, Fast-track designation Market size: ~4K patients per ovaria

  16. Slide 16: STRO-003 and Emerging Research Portfolio

    STRO-003 and Emerging Research Portfolio

  17. Slide 17: STRO-003 is a Novel Optimized ROR1 ADC, Featuring TOPO-1 Inhibitors

    STRO 003 Our Innovative Design: STRO-003 is a Novel Optimized ROR1 ADC, Featuring TOPO-1 Inhibitors Linked with β-Glucuronidase Cleavable Linkers, DAR 8 STRO-003 is a single homogeneous antibody drug 1 conjugate (ADC) with a drug-antibody ratio (DAR) of 8, ROR1 targeting ROR1 tumor antigen 1 Targete

  18. Slide 18: Drug Discovery Platform Enables Best-in-Class or First-in-Class Molecules

    Drug Discovery Platform Enables the Opportunity for Best-in-Class or First-in-Class Molecules Precise novel design to enhance efficacy and safety across multiple modalities and targets Conjugated Antibody Tumor Associated Antigen Targets ROR1 Tissue Factor Modality ADC iADC / ADC2 Bispecific ADC PTK

  19. Slide 19: New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC)

    New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC) Featuring dual drug conjugation technology with both cytotoxin and immune modulator Strategic iADC Collaboration June 27, 2022 • $90M upfront to develop iADCs for up to three targets • $422.5M in development, regulatory a

  20. Slide 20: Financial Overview

    Financial Overview Well-capitalized through multiple funding sources $287.3M (1) Projected cash runway into in cash, cash equivalents & 1H 2024(1), marketable securities as of based on current business plans and September 30, 2022 assumptions ~1.5M shares Funding generated from our collaborators of

  21. Slide 21: Experienced Leadership Team

    Experienced Leadership Team William Newell, JD Trevor Hallam, PhD Ed Albini, MBA Linda Fitzpatrick Chief Executive Officer and President of Research and Chief Financial Officer Chief People and Member of the Board of Chief Scientific Officer Communications Officer Directors Jane Chung, RPh Shabbir A

Sutro Biopharma — J.P. Morgan Healthcare Conference 2023 on 6ix